AlgoraeOS v1 Validated; New AI Platform Version Promises Smarter Drug Combos

Independent Validation Confirms AI Predictions

Algorae Pharmaceuticals has taken a significant step forward in AI-driven drug discovery with the successful independent validation of its AlgoraeOS version 1 (AOS1) platform. Conducted at the Victorian Centre for Functional Genomics within the Peter MacCallum Cancer Centre, the study tested 21 drugs predicted by AOS1 to synergize with cannabidiol (CBD) across four different cancer cell lines. The extensive preclinical program generated approximately 10,000 data points, providing a robust dataset to evaluate the platform's predictive accuracy.

The validation demonstrated that AlgoraeOS v1 could reliably identify drug combinations that exhibit true biological synergy, while effectively excluding those unlikely to work together. This was confirmed through multiple established synergy models, with three out of four showing strong correlation with the AI predictions. Such independent confirmation is a crucial milestone, underscoring the platform’s potential to streamline drug combination discovery by focusing laboratory resources on the most promising candidates.

From Validation to Innovation – Launch of AlgoraeOS v2

Building on the success of AOS1, Algorae has launched AlgoraeOS version 2 (AOS2), a major upgrade developed in collaboration with UNSW and CSIRO Data61. Trained on over 5.5 million unique inhibition records, AOS2 models the full dose-response landscape across multiple synergy frameworks and provides confidence-weighted predictions. Published benchmarks reveal that AOS2 outperforms leading AI models, including those developed by Google DeepMind, delivering more accurate and reliable predictions.

This advancement positions AlgoraeOS as a decision-grade tool for prioritising drug combinations in preclinical development, potentially accelerating the path from AI prediction to clinical application. The company anticipates releasing the first in silico predictions from AOS2 by December 2025, which will guide the selection of candidates for further laboratory testing.

Strategic Implications and Future Directions

Algorae’s validation and platform upgrade mark an important technical de-risking milestone, enhancing investor confidence in the company’s AI-driven approach. By effectively differentiating synergistic from non-synergistic drug pairs, AlgoraeOS can help optimise R&D investment and accelerate drug development timelines. The company plans to refine its scoring algorithms and reference models further, while expanding the platform’s application beyond oncology into other therapeutic areas through partnerships with leading research institutions.

Chief Scientific Officer Dr James McKenna highlighted the value of testing both positive and negative predictions, which has sharpened the platform’s capabilities and informed future preclinical program designs. As Algorae moves forward, the integration of AI with rigorous experimental validation could redefine how drug combinations are discovered and prioritised.